Inactive Instrument

Company Forward Pharma A/S

Equities

FWPAY

US34986J3032

Biotechnology & Medical Research

Business Summary

Forward Pharma A/S is a Denmark-based biopharmaceutical company, that commenced development in 2005 of a formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on Biogen's net sales of Tecfidera or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the 355 Patent Opposition Proceeding, including any appeal thereto.

Number of employees: 4

Managers

Managers TitleAgeSince
Chief Executive Officer 48 14-12-31
Comptroller/Controller/Auditor 67 14-07-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 65 16-05-05
Founder 55 05-06-30
Director/Board Member 65 06-05-31
Director/Board Member 63 15-06-30
Director/Board Member 52 15-06-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 343,926 23,553 ( 6.848 %) 0 6.848 %

Company contact information

Forward Pharma A/S

Strandvejen 125

2900, Hellerup

+45 33 44 42 42

http://www.forward-pharma.com
address Forward Pharma A/S(FWPAY)